CureVac B.V

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The late-stage clinical trial found high prevalence of virus variants.

CureVac shares tank 50% after preliminary data shows Covid vaccine is only 47% effective

Shares of Curevac NV tanked more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.

CureVac stock drops more than 50% on news trial COVID vaccine 47% effective

CureVac's stock tanked after the announcement. The German biotech blamed variants in a press release.

CureVac's COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotech

CVAC's COVID-19 vaccine may not be reviewed by regulatory authorities until August.

CureVac: The Moment Of Truth Is Delayed Until August

Aclaris Therapeutics

Hookipa Pharma Inc

Jiuzi Holdings

Ra Medical Systems Inc

The stock prices of RMED, HOOK, JZXN, ACRS, OPRA, and CVAC have fallen noticeably today. These are the details.

RMED, HOOK, JZXN, ACRS, OPRA, CVAC Stock Prices Fall Intraday

Ocugen, Inc.

Sanofi

Valneva SE

Arcturus Therapeutics

Novavax

Dr. Reddy's Labs

These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first on InvestorPlace.

7 Best Vaccine Stocks for Their Pipeline Potential

CVAC expects to finalize submission for regulatory approval of its COVID-19 vaccine this month.

CureVac: The Moment Of Truth Arrives

CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data. The company said an independent Data Safety Monitoring Board found no safety concerns for the vaccine, dubbed CV2CoV.

CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed

CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.

CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine

Novartis

Regeneron Pharmaceuticals

Repligen

Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.

Novartis (NVS) & Molecular Partners Initiate Study for COVID-19

The European regulator started a rolling review of the shot in February based on preliminary results from laboratory studies and early clinical studies in adults.

CureVac's Covid-19 Vaccine Has Important Role to Play in Fighting Variants, CEO Says

CureVac's CEO said the company's experimental COVID-19 vaccine can still play an important role in the pandemic fight given the “rapid spread” of concerning variants.

CureVac's COVID vaccine has important role to play in fighting variants, CEO says

Moderna

With COVID-19 vaccines still scarce around the world, companies are announcing plans to expand production so as to speed up vaccine distribution worldwide. CuraVac N.V.

Two COVID-19 vaccine makers in the news: CureVac and Moderna expanding production

Coupang

Equinor

Rada Electronic

XPeng

Here's a list of seven global stocks that can be added to the portfolio for exposure to growth themes from different regions. The post 7 Global Stocks That Are Worth Adding to Your Portfolio appeared first on InvestorPlace.

7 Global Stocks That Are Worth Adding to Your Portfolio

GlaxoSmithKline

CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-generation COVID-19 vaccine with signs that the candidate could also provide good protection against some variants of the virus.

CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study

BioNTech SE

BioNTech SE - ADR (NASDAQ: BNTX) shares were trading higher by 8.27% at $198.80 in Monday's premarket session after the company announced a Chinese joint venture to make 1 billion COVID-19 vaccine doses. BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases including COVID-19.

What's Up WIth BioNTech Stock And CureVac Stock Today?

CVAC is close to getting its COVID-19 vaccine approved in Europe. Its mRNA technology could potentially compete with PFE and MRNA.

CureVac Could Soon Join The Fight Against COVID-19

The promising data in mice needs to translate into humans.

CureVac's Vaccine Might Protect Against the South African Variant

Probably not, but at least one of them could make you thousands over time.

Could These 3 Brilliant mRNA Stocks Make You Millions?

Loncar China Biopharma ETF

Loncar Cancer Immunotherapy ETF

CRISPR Therapeutics

Editas Medicine

iShares Nasdaq Biotechnology ETF

Pfizer

Telesis Bio Inc

SPDR S&P Biotech ETF

Here is what you should know about investing in these life changing technologies.

Best Biotech Stocks & ETFs for mRNA, Gene Editing

Novartis is scaling up facilities to make COVID-19 vaccine doses for German drugmaker CureVac and could boost production beyond levels agreed so far, Chief Executive Vas Narasimhan said on a conference call on Tuesday.

Novartis CEO says could boost CureVac vaccine production, if needed

The biotech still has a long way to go to prove itself and justify its current stock valuation.

CureVac's Potential Has Wall Street Sending Mixed Signals

A big market is in big need of more vaccines.

2 Reasons This COVID Vaccine Latecomer Could Gain Major Market Share

Immunic Inc

Inovio Pharmaceuticals

PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday.

Why PPD, Immunic, Inovio and CureVac Shares Are Higher Today

The German company, which went public last August, said its vaccine is in the final stage of clinical development.

CureVac says it is on track with COVID-19 vaccine as it posts earnings update

News for CureVac B.V Stock (CVAC)